Sole-Therapy Treatment of Atrial Fibrillation (RESTORE SR II)
This study is ongoing, but not recruiting participants.
Sponsor:
AtriCure, Inc.
Information provided by (Responsible Party):
AtriCure, Inc.
ClinicalTrials.gov Identifier:
NCT00566176
First received: November 30, 2007
Last updated: February 4, 2013
Last verified: February 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
RESTORE SR II is a feasibility study on the minimally invasive use of the AtriCure Bipolar System for PV Isolation on a beating heart for the treatment of all types of atrial fibrillation in a sole therapy operation (not concomitant to another cardiac operation).
| Condition | Intervention | Phase |
|---|---|---|
|
Atrial Fibrillation |
Device: Surgical Ablation using the AtriCure Bipolar System |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Thoracoscopically-Assisted Epicardial Bilateral Pulmonary Vein Isolations Using the AtriCure Bipolar System and Exclusion of the Left Atrial Appendage for the Treatment of Atrial Fibrillation |
Resource links provided by NLM:
Genetics Home Reference related topics:
familial atrial fibrillation
MedlinePlus related topics:
Atrial Fibrillation
U.S. FDA Resources
Further study details as provided by AtriCure, Inc.:
Primary Outcome Measures:
- The primary outcome is the feasibility of performing this operation by demonstrating the ability to consistently isolate the right and left PVs using this minimally invasive approach. [ Time Frame: Perioperatively ] [ Designated as safety issue: No ]
- The primary safety endpoint will be determined by assessing the rate of serious adverse events. [ Time Frame: Discharge/30 Days ] [ Designated as safety issue: Yes ]
| Enrollment: | 25 |
| Study Start Date: | October 2005 |
| Estimated Study Completion Date: | February 2017 |
| Primary Completion Date: | December 2007 (Final data collection date for primary outcome measure) |
Intervention Details:
-
Device: Surgical Ablation using the AtriCure Bipolar System
Surgical Ablation using the AtriCure Bipolar System
Eligibility| Ages Eligible for Study: | 18 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Male or female patient between 18 and 80 years of age
Patient with symptomatic AF and failure or intolerance of one or more Class I or Class III AADs and:
- Who describes 3 or more symptomatic AF episodes during the 6 month period prior to enrollment, with at least 1 electrocardiographically documented episode of AF in the 4 months prior to enrollment or,
- Who has documented AF within the 6 months proceeding enrollment that did not terminate spontaneously (including patients in continuous AF) or,
- Who is unwilling or unable to take anticoagulants, with 3 or more symptomatic episodes during the 6 month period prior to enrollment with at least 1 electrocardiographically documented episode of AF in the 4 months prior to enrollment.
- Left Atrial Size < 6 cm (determined by echocardiography performed within 60 days of enrollment), unless the LV dysfunction is thought to result (at least in part) from AF
- Left Ventricular Ejection Fraction ≥ 30% (determined by echocardiography performed within 60 days of enrollment)
- Patient is willing and able to provide written informed consent.
- Patient has a life expectancy of at least 2 years.
- Patient is willing and able to attend the scheduled follow-up visits.
- Weight < 325 lbs
Exclusion Criteria:
- Prior cardiac catheter ablation for the treatment of arrhythmia within 4 months
- Prior cardiac surgery
- Patients requiring any open heart procedure (e.g. CABG, valve replacement or repair, atrial septal defect repair, etc.)
- Class IV NYHA heart failure symptoms, unless these symptoms are considered to be due to uncontrolled AF
- Cerebrovascular accident within previous 6 months
- Known carotid artery stenosis greater than 80%
- Evidence of significant active infection
- Patient unable to undergo TEE
- Pregnant woman
- Requires anti-arrhythmic drug therapy for the treatment of ventricular arrhythmia
- Presence of thrombus in the left atrium
- Patient has co-morbid condition that in the opinion of the investigator poses undue risk of general anesthesia or port access cardiac surgery
- Patient is enrolled in another investigational study
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00566176
Locations
| United States, Florida | |
| University Community Hospital/Dr. Kiran C. Patel Research Institute | |
| Tampa, Florida, United States, 33616 | |
| United States, Ohio | |
| University of Cincinnati | |
| Cincinnati, Ohio, United States, 45267 | |
| United States, Oklahoma | |
| University of Oklahoma Cardiac Arrythmia Research Institute | |
| Oklahoma City, Oklahoma, United States, 73104 | |
| United States, Oregon | |
| Sacred Heart Medical Center Endovascular Research | |
| Eugene, Oregon, United States, 97401 | |
| United States, Texas | |
| Medical City Hospital/Cardio Pulmonary Research Science and Technology Institute | |
| Dallas, Texas, United States, 75230 | |
Sponsors and Collaborators
AtriCure, Inc.
Investigators
| Principal Investigator: | Warren Jackman, MD | University of Oklamhoma Cardiac Arrythmia Research Institute |
| Principal Investigator: | James Edgerton, MD | Medical City Hospital/Cardio Pulmonary Research Science and Technology Institute |
More Information
No publications provided
| Responsible Party: | AtriCure, Inc. |
| ClinicalTrials.gov Identifier: | NCT00566176 History of Changes |
| Other Study ID Numbers: | CP2005-1 |
| Study First Received: | November 30, 2007 |
| Last Updated: | February 4, 2013 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by AtriCure, Inc.:
|
Atrial Fibrillation AF AFIB racing heart |
pulmonary vein isolation pvi mini maze maze |
Additional relevant MeSH terms:
|
Atrial Fibrillation Arrhythmias, Cardiac Heart Diseases Cardiovascular Diseases Pathologic Processes |
ClinicalTrials.gov processed this record on May 19, 2013